



PAUL COHEN'S

Marijuana Hub

A Division of Cohen Grassroots Research, Inc. www.cohengrassroots.com



Newsletter: July 17, 2015, Issue #167 -- www.cohenresearch.com

Cohen Grassroots Research, Inc. is the Nation's Number #1 Micro Cap and Cannabis Research Firm
IR Research Reports (1,000+) - Distribution to 100s of thousands of investors

HOW TO MAKE MONEY IN THE MARIJUANA STOCK MARKET

CANNABIS SCIENCE, INC. CBIS

Today, Alan Brochstein posted the following email on his 420 Investor service: "I posted what seems like yet another worthless press release by CBIS to the Forum. The title alone is enough to suggest that this is one of the lamest companies in the sector pretending to be a real cannabis-focused company:

Cannabis Science, Inc. Initiates the Scientific Validation of the Biological Impact of Cannabinoids in Order to Better Define the Therapeutic Mechanism of Action Using Biochemical, Cell, and Genetic Approaches. CBIS has been burning investors for over six years, yet it has the audacity to say that it has "prepared the blueprint for establishing basic science exploration and explanation for medicinal benefits associated with cannabinoid products." What has it been doing for the past six years???

Brochstein has been sued by one issuing company for trashing that issuing company. He went to his subscriber list to create a legal defense fund which raised funds to defend himself. He continues to trash what and who he chooses.

His trading recommendation record may be the worst of any Wall Street analyst or subscription analyst in any industry group of public issuing companies. His record is on his website. If we were to assume adding commissions to all of his hundreds of trade recommendations, YTD and 365 days ago, his losses could be well in the -50% to -75% or more for his investor group. His resume does not include the CMT 1, 2, or 3 Level trading credential. To vend his trading advice, it should. He continues to recommend buy trading recommendations in a Bear Market.

CBIS is a highly credentialed pioneer in cannabis science. Perhaps any major Wall Street brokerage firm would require an analyst with a scientific educational background to follow Medical marijuana. Brochstein's resume reports no scientific background for analyzing Medical cannabis science. Regarding CBIS, he is dead wrong. His blog is intended to defame CBIS. It hurts the industry as a whole, hurts the marijuana stock market, and creates a continual illusion that the industry is full of scam companies. CBIS is not one such company.